Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-09-21

Clinical Trial Update: Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

Safety study results for VM202 in amyotrophic lateral sclerosis (Phase 1/Phase 2) have been completed, and results were posted in September 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VM202 (hepatocyte growth factor gene therapy)

Snippet

Sponsor: Helixmith Co., Ltd. | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-09-21